We are pleased to announce our expansion to a larger facility and our plan to add 40 new jobs over the next 2-3 years. The new facility that we leased in downtown Tampa at 401 S. Florida Avenue has more than 14,000 square feet. It provides enough space for the company to consolidate its corporate...
We are pleased to announce that our Co-Founder and CEO, Sean Fetcho, was recently featured as a guest on the Healthcare Executive Insights Podcast, presented by The Macallan Group. The latest episode titled “Uncovering The Truth Behind Healthcare Systems” is now available for streaming on YouTube, Spotify, and Apple Podcasts. During the podcast, Sean shares...
Members of our Verséa Biologics team (Sunil Panchal, MD, Chief Scientific Officer, Verséa Biologics; David Kloth, M.D., Medical Director, Verséa Biologics; and Bill Bigham, VP of Sales, Verséa Biologics) attended this year’s North American Neuromodulation Society 26th Annual Meeting. At the event they had a chance to present our innovative portfolio of Biologics products which...
Verséa Ophthalmics invites you to attend the Hawaiian Eye 2023 – Disruptive Innovations Symposium on January 16th from 1pm – 2:30pm HST where Dr. Rob Sambursky, our President, will be presenting the latest Eye Care innovations: Novel, Tear-based Point-of-care (POC) diagnostic platform with 2 quantitative tests, Complementary regenerative therapeutics. These innovative solutions will help you...
Verséa Ophthalmics is a proud sponsor of this year’s 2022 CEDARS/ASPENS Annual Meeting, taking place today and tomorrow at JW Marriott Camelback, Scottsdale (AZ). CEDARS/ASPENS is a not-for-profit society whose mission is to expand the knowledge of ophthalmic surgery and foster excellence in patient care through clinical experience, peer-to-peer exchange, and practice education. Their mission...
As part of the corporate exhibit hall interview series at the Eyes On 2023, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Brittany J. McMurren, OD. During the interview, titled “A Deep Dive into New Testing & Therapeutic Innovations” Rob Sambursky, MD presented new testing and therapeutic innovations that Verséa Ophthalmics is bringing to...
Following the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held in Chicago, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Ophthalmology Times to provide an overview of the company and its products. Dr. Sambursky spoke about BIOVANCE 3L Ocular, a 3-layered decellularized, dehydrated human amniotic membrane (DDhAM) designed for comfort and improved handleability,...
This week Verséa Ophthalmics team is presenting at the American Academy of Optometry AAOpt 2022 Meeting in San Diego (CA). Visit our booth # 405, where we will be demonstrating our new Tear-Based Point of Care (T-POC) Quantitative Testing Platform that consists of a portable, multifunctional reader and two tear-based quantitative biomarker test kits: –...
At this year’s NACS Show 2022 Verséa Holdings, Inc. is launching their new business division Verséa Health and their Product Line Portfolio Verséa Easy Lab™. James Olin, Chief Commercial Officer at Verséa, explains the reason behind the launch: “Verséa Health was created with a mission to give millions of Americans direct-access to the most essential...
© 2024 Verséa Health, Inc. All rights reserved.
